Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study observed that the incidence of hair loss as a spontaneously reported side effect of novel oral anticoagulant therapy is approximately 4.4 per 100 patient years.

This paper describes the development of diagnostic criteria for several enduring sexual dysfunction conditions following the use of certain medications, highlighting common sexual and non-sexual symptoms.

This study found that non-bleeding adverse events associated with NOACs affect multiple organ systems, emphasizing the importance of clinical vigilance. Specific NOACs like dabigatran, apixaban, edoxaban, and rivaroxaban were linked to distinct adverse reactions, including metabolic imbalances, thyroid disorders, and menstrual irregularities.

This review discusses the introduction of new oral anticoagulants for atrial fibrillation and highlights their safety and the development of reversal agents, but reports no new clinical findings.

This case report suggests that hair loss may be a potential adverse effect of rivaroxaban, though it is not listed in the product characteristics.